The occurrence of acute brain lesions was lower with a transseptal puncture than with a conventional retrograde aortic approach in patients undergoing left ventricular catheter ablation, with no ...
Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Among patients who underwent transcatheter valve-in-valve repair of a failed surgical mitral ...
DUBLIN, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval to begin an early feasibility study (EFS) for its ...
Edwards Lifesciences EW announced that the FDA approved its SAPIEN M3 transcatheter mitral valve replacement system, making it the first minimally invasive, catheter-based treatment that uses a ...
Please provide your email address to receive an email when new articles are posted on . At 1 year, leaflet transcatheter mitral valve repair demonstrated low rate of complications, high survival and ...
SAN FRANCISCO, CA—Transcatheter mitral valve-in-valve procedures, especially those done via transseptal access, are associated with low mortality and adverse event rates as well as quality-of-life ...
The Sapien M3 transcatheter mitral valve replacement system won FDA approval -- making it the first on the market to utilize ...
Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...
ENGLEWOOD, Colo., June 26, 2025 /PRNewswire/ -- CIRCA Scientific today announced the successful completion of the Limited Market Release (LMR) for its CrossWise™ RF Transseptal Access System, a key ...
LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology company, today announced the conclusion of the PRELUDE feasibility study for its Caisson Transcatheter Mitral ...
InnovHeart may not have grown three sizes in one day, but it’s gotten quite a boost from the recent close of its series C funding round. The Milan-based company makes transcatheter mitral valve ...
Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach to receive U.S. Food and ...